Mallory Grant W, Pollock Bruce E, Foote Robert L, Carlson Matthew L, Driscoll Colin L, Link Michael J
*Departments of Neurologic Surgery, ‡Radiation Oncology, and §Otolaryngology-Head and Neck Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota.
Neurosurgery. 2014 Mar;74(3):292-300; discussion 300-1. doi: 10.1227/NEU.0000000000000264.
Management of neurofibromatosis type 2 (NF2)-associated vestibular schwannomas (VSs) remains controversial. Stereotactic radiosurgery (SRS) with conventional dosing is less effective for NF2-related VS compared with sporadic lesions.
To evaluate optimal SRS dose parameters for NF2-related VS and to report long-term outcomes.
A prospective database was reviewed and outcome measures, including radiographic progression, American Academy of Otolaryngology-Head and Neck Surgery hearing class, and facial nerve function, were analyzed. Progression-free survival was estimated with Kaplan-Meier methods. Associations between tumor progression and radiosurgical treatment parameters, tumor volume, and patient age were explored with the use of Cox proportional hazards regression.
Between 1990 and 2010, 26 patients with 32 NF2-related VSs underwent SRS. Median marginal dose and tumor volume were 14 Gy and 2.7 cm, respectively. Twenty-seven tumors (84%) showed no growth (median follow-up, 7.6 years). Kaplan-Meier estimates for 5- and 10-year progression-free survival were 85% and 80%, respectively. Cox proportional hazards demonstrated a significant inverse association between higher marginal doses and tumor progression (hazard ratio, 0.49; 95% confidence interval, 0.17-0.92; P = .02). Audiometric data were available in 30 ears, with 12 having class A/B hearing before SRS. Only 3 maintained serviceable hearing at the last follow-up. Four underwent cochlear implantation. Initially, 3 achieved open-set speech recognition, although only 1 experienced long-term benefit. Facial nerve function remained stable in 50% of cases.
Higher marginal doses than commonly prescribed for sporadic VS were associated with improved tumor control in patients with NF2. Hearing outcomes were poor even when contemporary reduced marginal doses were used. However, SRS allows an anatomically preserved cochlear nerve and may permit hearing rehabilitation with cochlear implantation. Further consideration should be given to optimum dosing to achieve long-term control while maximizing functional outcomes.
HB, House-BrackmannNF2, neurofibromatosis type 2SRS, stereotactic radiosurgeryVS, vestibular schwannoma.
2型神经纤维瘤病(NF2)相关前庭神经鞘瘤(VS)的治疗仍存在争议。与散发性病变相比,采用传统剂量的立体定向放射外科治疗(SRS)对NF2相关VS的疗效较差。
评估NF2相关VS的最佳SRS剂量参数并报告长期疗效。
回顾前瞻性数据库并分析包括影像学进展、美国耳鼻咽喉-头颈外科学会听力分级及面神经功能等疗效指标。采用Kaplan-Meier法估计无进展生存期。利用Cox比例风险回归探讨肿瘤进展与放射外科治疗参数、肿瘤体积及患者年龄之间的关联。
1990年至2010年间,26例患有32个NF2相关VS的患者接受了SRS治疗。边缘剂量中位数和肿瘤体积分别为14 Gy和2.7 cm³。27个肿瘤(84%)无生长(中位随访时间7.6年)。Kaplan-Meier法估计的5年和10年无进展生存率分别为85%和80%。Cox比例风险分析显示较高的边缘剂量与肿瘤进展之间存在显著负相关(风险比,0.49;95%置信区间,0.17 - 0.92;P = 0.02)。有30耳可获得听力测定数据;其中12耳在SRS治疗前为A/B级听力。最后一次随访时仅3耳仍保留有效听力。4例接受了人工耳蜗植入。最初,3例实现了开放式言语识别,但只有1例获得长期受益。50%的病例面神经功能保持稳定。
与散发性VS常用剂量相比,较高的边缘剂量与NF2患者更好的肿瘤控制相关。即使采用当代降低的边缘剂量,听力结果仍较差。然而,SRS可保留解剖学上的耳蜗神经,并可能允许通过人工耳蜗植入进行听力康复。应进一步考虑最佳剂量,以实现长期控制并最大化功能结果。
HB,House-Brackmann分级;NF2,2型神经纤维瘤病;SRS,立体定向放射外科治疗;VS,前庭神经鞘瘤